Alumis and Acelyrin Approve Merger Proposal, Proxy Statement Filed
Deal News | Apr 04, 2025 | EIN
Alumis Inc. and ACELYRIN, Inc., both biopharmaceutical companies listed on NASDAQ, have submitted a joint definitive proxy statement/prospectus to the U.S. SEC, detailing their proposed merger. This significant merger promises to leverage the strengths of both companies, creating a late-stage biopharma powerhouse focused on immune-mediated diseases. The merger, recommended unanimously by both boards of directors, is expected to finalize by the second quarter of 2025. Post-merger, Alumis stockholders will own approximately 55% of the new entity, while ACELYRIN stockholders will control the remaining 45%. The combined company is anticipated to benefit from both a robust pipeline and extended financial runway, with pro forma cash of $737 million as of December 2024, providing operational security into 2027. In-depth clinical trials for therapies addressing psoriasis, lupus, and multiple sclerosis are planned post-merger, alongside the development of lonigutamab, a promising treatment for thyroid eye disease. Special meetings for stockholder voting have been scheduled for May 13, 2025.
Sectors
- Biopharmaceuticals
- Immunotherapy
Geography
- United States – Both Alumis and ACELYRIN are based in California, and the SEC, which they are filing documentation with, is a United States regulatory body, placing the primary geographical focus of this merger within the United States.
Industry
- Biopharmaceuticals – The article focuses on the merger of two biopharmaceutical companies, Alumis and ACELYRIN. Both companies are engaged in the development of therapies for immune-mediated diseases, which positions them squarely in this industry.
- Immunotherapy – Alumis and ACELYRIN are concentrated on developing transformative therapies in the field of immunology, particularly for immune-mediated diseases, making immunotherapy a core aspect of their business.
Financials
- 737 million – Pro forma cash of the combined company providing a financial runway into 2027, as of December 31, 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Alumis Inc. | Target company | Company | A clinical-stage biopharmaceutical company focused on developing precision therapies for immune-mediated diseases. |
| ACELYRIN, Inc. | Selling company | Company | A late-stage clinical biopharma company focused on developing transformative medicines in immunology. |
| U.S. Securities and Exchange Commission | Regulatory body | Government | The U.S. SEC is the regulatory authority overseeing the merger documentation for Alumis and ACELYRIN. |
| MacKenzie Partners, Inc. | Proxy solicitor for Alumis | Company | A firm assisting Alumis stockholders with proxy materials for the merger. |
| Sodali & Co. | Proxy solicitor for ACELYRIN | Company | A firm assisting ACELYRIN stockholders with proxy materials for the merger. |